Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLLT1 | Q03111 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 8/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | UBE2N | P61088 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 2/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7072759 | 0.88 | TNKS (0.41) | MLLT1MAPTACSS2 | |
| SCHEMBL7070345 | 0.82 | TRPV1 (0.37) | MAPTALDH1A1ACSS2POLBHSD17B10 | |
| SCHEMBL7071918 | 0.80 | ITGB3 (0.39) | ACSS2 | |
| SCHEMBL7071802 | 0.80 | TPSAB1 (0.37) | MAPTACSS2TP53HPGDHTT | |
| SCHEMBL7067672 | 0.79 | MLLT1 (0.41) | MLLT1MAPTALDH1A1POLBGAA | |
| SCHEMBL7075123 | 0.79 | PDE4A (0.42) | MAPTKDM4EPOLBHPGD | |
| SCHEMBL7072722 | 0.78 | MAPT (0.38) | MAPTACSS2HPGD | |
| SCHEMBL7067665 | 0.78 | TPSAB1 (0.36) | MAPTACSS2 | |
| SCHEMBL7075972 | 0.77 | CYP1A2 (0.37) | MAPTALDH1A1KDM4EACSS2HPGD | |
| SCHEMBL7073370 | 0.77 | TPSAB1 (0.42) | HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212120-A1 | Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders | AXYS PHARMACEUTICALS, INC. (US) | 2003-11-13 | — | — | US | disclosed |
| US-6562854-B2 | Antiinflammatory agents; respiratory system disorders | AXYS PHARMACEUTICALS, INC. | 2003-05-13 | — | — | US | disclosed |
| US-20010053779-A1 | Novel compounds and compositions for treating diseases asociated with protease activity | Celera Corporation | 2001-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010053779-A1 | Novel compounds and compositions for treating diseases asociated with protease activity | CMA1, CPA3, TPSG1 | MLLT1 4411/4885MAPT 2104/4885ALDH1A1 1860/4885 |
| US-20030212120-A1 | Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders | CMA1, TPSG1, TPSD1 | MLLT1 3937/4885MAPT 2289/4885ALDH1A1 729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.